- Status Pre-assessment
- Type New application
- Pre-PASC consultation Closed
- Pre-MSAC consultation Not yet started
- Outcome Pending
Application details
Reason for application
New MBS item.
Service or technology in this application
The ArteraAI Prostate Biopsy Assay is a software device based on artificial intelligence that assesses clinical information about a patient with localised prostate cancer in combination with digital images from the patients’ prostate biopsy. The AI then predicts whether a patient with intermediate risk localised prostate cancer who is planned to undergo curative-intent radiotherapy would benefit from hormone therapy in the short-term and their longer term prognosis.
Type: Investigative technology
Medical condition this application addresses
Prostate cancer is cancer that forms in the tissues of the prostate. Australia has one of the highest incidence rates of prostate cancer with around 1 in 6 men diagnosed by age 85. Advances in early detection and management focus on minimising harm and reducing overdiagnosis and overtreatment.
Application documents
Application summary
PICO set
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Consultation survey and deadlines
- PASC consultation: Closed Friday 8 November 2024.
Any consultation received after this date will automatically be included in the MSAC consultation for this application. - MSAC consultation: TBA – please subscribe to the MSAC email bulletin to be notified when this application is scheduled for MSAC consideration. The bulletin will also advise the closing date for consultation input.
Meetings to consider this application
- PASC meeting: 12–13 December 2024
- ESC meeting: -
- MSAC meeting: -
Outcome details
The outcome of this application is pending.